Advanced Search
Welcome to the Systematic
Review Data Repository
Welcome to the Systematic Review Data Repository
The Systematic Review Data Repository (SRDR) is a powerful and easy-to-use tool for the extraction and management of data for systematic review or meta-analysis. It is also an open and searchable archive of systematic reviews and their data.

To contribute data or comment on deposited projects, simply Register for an account.


Registered users, log in below:
Forgot Password?

Recently Completed and Deposited Reports Data

Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma [Retrospectively Entered]


Public Report Complete
Statistics: 281 Studies, 9 Key Questions, 9 Extraction Forms,
Date Created: Jun 26, 2014 06:17PM
Description: Hepatocellular carcinoma (HCC) is the most common primary malignant neoplasm of the liver, and accurate diagnosis and staging of HCC are important for guiding treatment and other clinical decisions. A number of imaging modalities are available for detection of HCC in surveillance and non-surveillance settings, evaluation of focal liver lesions to identify HCC, and staging of HCC. The purpose of this review is to compare the effectiveness of imaging techniques for HCC on test performance, clinical decisionmaking, clinical outcomes, and harms.

Home-Based Primary Care Interventions [Retrospectively Entered]


Public Report Complete
Statistics: 20 Studies, 3 Key Questions, 1 Extraction Form,
Date Created: Jul 29, 2015 04:56PM
Description: Objective. To assess the available evidence about home-based primary care (HBPC) interventions for adults with serious or disabling chronic conditions. Data sources. Articles from January 1998 through May 2015 were identified using Ovid MEDLINE, CINAHL, Clinical Trials.gov, Cochrane Database of Systematic Reviews, reference lists, and gray literature databases. Review methods. We included randomized controlled trials (RCTs) and observational studies of HBPC, including home visits by a primary care provider, longitudinal management, and comprehensive care. Study quality was assessed, data extracted, and results summarized qualitatively. Results. We identified 4,406 citations and reviewed 219 full-text articles; 19 studies were included. Two were RCTs while 17 were observational studies. The strongest evidence (moderate) was that HBPC reduces hospitalizations and hospital days. Reductions in emergency and specialty visits and in costs were supported by less strong evidence, while no or unclear effects were identified on hospital readmissions and nursing home days. Evidence about clinical outcomes was limited to studies that reported no significant differences in function or mortality. HBPC had a positive impact on patient and caregiver experience, including satisfaction, quality of life, and caregiver needs, but the strength of evidence for these outcomes was low. In studies that reported on the impact of patient characteristics, moderate evidence indicated frail or sicker patients are more likely to benefit from HBPC. No identified studies assessed the impact of organizational characteristics. No adverse events were reported. Only one study examined the potential for a negative impact; none was found. The services included in the HBPC interventions varied widely, and no identifiable combination was related to more positive outcomes. We did identify four studies that evaluated the addition of specific services. Combining palliative care and primary care home visits increased the likelihood of death at home (low strength of evidence), while studies on adding caregiver support (one study) or transitional care (one study) to HBPC were rated as insufficient evidence. Conclusions. Current research evidence is generally positive, providing moderate-strength evidence that HBPC reduces utilization of inpatient care, and providing low-strength evidence about its impact on utilization of other health services, costs, and patient and caregiver experience. Future research should focus on the content and organizational context of HBPC interventions so that experiences can be replicated or improved on by others. Additional research is also needed about which patients benefit most from HBPC and how HBPC can be best used in the continuum of care.

Strategies to Improve Mental Health Care for Children and Adolescents


Public Report Complete
Statistics: 14 Studies, 3 Key Questions, 1 Extraction Form,
Date Created: Mar 11, 2015 03:21PM
Description: To increase knowledge about the effectiveness of quality improvement (QI), implementation, and dissemination strategies that seek to improve the mental health care of children and adolescents; to examine harms associated with these strategies; and to determine whether effectiveness or harms vary in subgroups based on system, organizational, practitioner, or patient characteristics.

Home-Based Primary Care Interventions [Retrospectively Entered]


Public Report Complete
Statistics: 20 Studies, 3 Key Questions, 1 Extraction Form,
Date Created: Jul 29, 2015 04:56PM
Description: Objective. To assess the available evidence about home-based primary care (HBPC) interventions for adults with serious or disabling chronic conditions. Data sources. Articles from January 1998 through May 2015 were identified using Ovid MEDLINE, CINAHL, Clinical Trials.gov, Cochrane Database of Systematic Reviews, reference lists, and gray literature databases. Review methods. We included randomized controlled trials (RCTs) and observational studies of HBPC, including home visits by a primary care provider, longitudinal management, and comprehensive care. Study quality was assessed, data extracted, and results summarized qualitatively. Results. We identified 4,406 citations and reviewed 219 full-text articles; 19 studies were included. Two were RCTs while 17 were observational studies. The strongest evidence (moderate) was that HBPC reduces hospitalizations and hospital days. Reductions in emergency and specialty visits and in costs were supported by less strong evidence, while no or unclear effects were identified on hospital readmissions and nursing home days. Evidence about clinical outcomes was limited to studies that reported no significant differences in function or mortality. HBPC had a positive impact on patient and caregiver experience, including satisfaction, quality of life, and caregiver needs, but the strength of evidence for these outcomes was low. In studies that reported on the impact of patient characteristics, moderate evidence indicated frail or sicker patients are more likely to benefit from HBPC. No identified studies assessed the impact of organizational characteristics. No adverse events were reported. Only one study examined the potential for a negative impact; none was found. The services included in the HBPC interventions varied widely, and no identifiable combination was related to more positive outcomes. We did identify four studies that evaluated the addition of specific services. Combining palliative care and primary care home visits increased the likelihood of death at home (low strength of evidence), while studies on adding caregiver support (one study) or transitional care (one study) to HBPC were rated as insufficient evidence. Conclusions. Current research evidence is generally positive, providing moderate-strength evidence that HBPC reduces utilization of inpatient care, and providing low-strength evidence about its impact on utilization of other health services, costs, and patient and caregiver experience. Future research should focus on the content and organizational context of HBPC interventions so that experiences can be replicated or improved on by others. Additional research is also needed about which patients benefit most from HBPC and how HBPC can be best used in the continuum of care.

Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer


Public Report Complete
Statistics: 199 Studies, 8 Key Questions, 1 Extraction Form,
Date Created: May 18, 2015 07:06PM
Description: Objectives. Non-muscle-invasive bladder cancer (NMIBC) frequently recurs and can progress to muscle-invasive disease. This report reviews the current evidence on emerging approaches to diagnosing and treating bladder cancer. Data Sources. Electronic databases (Ovid MEDLINE, January 1990 – October 2014; Cochrane Central Register of Controlled Trials, through September 2014; Cochrane Database of Systematic Reviews, through September 2014; Health Technology Assessment, through 3rd Quarter, 2014; National Health Sciences Economic Evaluation Database, through 3rd Quarter, 2014; and Database of Abstracts of Reviews of Effects, through 3rd Quarter, 2014), references lists, and clinical trials registries. Review Methods. Using predefined criteria, we selected studies on diagnostic accuracy of urinary biomarkers versus cystoscopy, and trials of fluorescent cystoscopy, intravesical therapy, and radiation therapy for NMIBC that evaluated bladder cancer recurrence, progression, mortality, or harms. The quality of included studies was assessed, data were extracted, and results were summarized qualitatively and using meta-analysis. Results. Urinary biomarkers were associated with sensitivity for bladder cancer that ranged from 0.57 to 0.82 and specificity from 0.74 to 0.88, for positive likelihood ratios from 2.52 to 5.53 and negative likelihood ratios from 0.21 to 0.48 (strength of evidence [SOE]: moderate for quantitative nuclear matrix protein 22 [NMP22], qualitative bladder tumor antigen [BTA], fluorescent in situ hybridization [FISH], and ImmunoCyt; low for other biomarkers). Sensitivity increased for higher stage and grade tumors. Studies that directly compared the accuracy of quantitative NMP22 and qualitative BTA found no differences in diagnostic accuracy (SOE: moderate). Most trials found fluorescent cystoscopy associated with decreased risk of subsequent bladder recurrence versus white light cystoscopy, but results were inconsistent, and there was no difference in risk of progression or mortality (SOE: low). Intravesical therapy was more effective than no intravesical therapy for reducing risk of bladder cancer recurrence (for bacillus Calmette-Guérin [BCG], RR 0.56, 95% CI 0.43 to 0.71, SOE: moderate; for mitomycin C [MMC], doxorubicin, and epirubicin, RR 0.66 to 0.72, SOE: moderate). BCG was also associated with decreased risk of bladder cancer progression, but no intravesical agent was associated with decreased risk of all-cause or bladder-cancer specific mortality. Intravesical therapy appeared to be effective across subgroups defined by tumor stage, grade, multiplicity, recurrence status, and size (SOE: low). Evidence was too limited to draw strong conclusions regarding effects of dose or duration of therapy on effectiveness. Compared with no intravesical therapy, BCG was associated with a higher rate of local and systemic adverse events (granulomatous cystitis or irritative symptoms in 27% to 84% of patients, macroscopic hematuria in 21% to 72%, and fever in 27% to 44%) (SOE: low). Compared with MMC, BCG was also associated with an increased risk of local adverse events and fever (SOE: low). One randomized trial found no difference between radiation therapy and no radiation therapy in clinical outcomes in patients with T1G3 cancers. Conclusions. Urinary biomarkers miss a substantial proportion of patients with bladder cancer, and additional research is needed to clarify advantages of fluorescent cystoscopy over white light cystoscopy. Intravesical therapy reduces risk of bladder cancer recurrence versus no intravesical therapy. BCG is the only intravesical therapy shown to be associated with decreased risk of bladder cancer progression, but is associated with a high rate of adverse events. More research is needed to define optimal doses and regimens of intravesical therapy.

Dietary Fiber Database, Version 1


Public Report Complete
Statistics: 869 Studies, 1 Key Question, 1 Extraction Form,
Date Created: Apr 27, 2015 09:35PM
Description: The objectives of this database are to: 1. Systematically compile and provide access to primary, English-language, peer-reviewed science linking dietary fiber intake in humans to one or more of 9 potential health benefits 2. Provide researchers with a tool to understand how different fibers are characterized in studies 3. Facilitate researchers in identifying gaps in the current research 4. Create a database to serve as a starting foundation of primary human literature for conducting evidence-based reviews and meta-analyses 5. Efficiently assist researchers in identifying fibers of interest This database should serve as a foundation for future work. Specific inclusion and exclusion criteria, detailed in the user manual, were applied in determining database eligibility; thus, this database is not intended to serve as a sole source for identifying all possible fiber literature for the purposes of conducting a meta-analysis or systematic review. This database contains Population, Intervention, Comparator, and Outcome (PICO) data to help users formulate and narrow the focus of their research question. It is expected that secondary searches will be conducted to augment this database.



Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/

Popular Resources



Help


SRDR Announcements


 

Statistics



Maintenance Schedule